OSA consequences and their reversibility just by resolving OSA
| Usually reversible (at least partially) | Reversibility undetermined | Usually irreversible |
|---|---|---|
| Gout flares—immediately [43] | Coronary [75]/peripheral [76, 77] artery disease | Residual MSU with hyperuricemia [91, 92] |
| Atrial fibrillation—6 months [44] | Dyslipidemia/atherosclerosis [78] | Myocardial infarction [93] |
| Hypercoagulability—6 months [45, 46] | Congestive heart failure [79] | Ischemic stroke [94, 95] |
| Chronic kidney disease—3 months [47–49] | Autoimmune diseases [80, 81] | Type 2 diabetes [96, 97] |
| Ventricular mechanical dysfunction—3 months [50] | Chronic migraine [82] | Cancer [98–103] |
| Hypertension—6 months [51–53] | Hypothyroidism [83] | Mitral valve disease [104] |
| Nonalcoholic fatty liver disease [54, 55] | Systemic inflammation [84] | Aortic valve stenosis [105] |
| Excessive daytime sleepiness [56] | Erythrocytosis/polycythemia [85] | Interstitial lung disease [106, 107] |
| Nocturia [57] | Insomnia [86] | - |
| Cognitive impairment—1 year [58–60] | Keratoconus [87] | - |
| Depression—4 months [61, 62] | Female infertility [88] | - |
| Erectile dysfunction [63–65] | Glaucoma [89] | - |
| Endothelial dysfunction—3 months [66] | Inflammatory bowel disease [90] | - |
| Gastroesophageal reflux [67–71] | - | - |
| Rate of Alzheimer’s disease progress [72] | - | - |
| Telomere shortening—6 months [73, 74] | - | - |
-: blank cell